LOS ANGELES--(BUSINESS WIRE)--
Lundin Law PC (the “Firm”) announces the filing of a class action lawsuit against Seres Therapeutics, Inc. (“Seres Therapeutics” or the “Company”) (Nasdaq: MCRB) concerning possible violations of federal securities laws between June 25, 2015 and July 29, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the November 28, 2016 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The complaint alleges that during the Class Period, Seres Therapeutics made materially false and misleading statements and/or failed to disclose material facts about its lead drug product candidate SER-109, touting its potential and efficacy. On July 29, 2016, the Company announced that the Phase 2 clinical trial of SER-109 did not meet its primary endpoint. When this information was released to the public, shares of Seres Therapeutics lowered in value, which caused investors harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160930005557/en/
